Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Authors:
Open Access
- 1 September 2011
- journal article
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 9 (3) , 468-477
Abstract
In parallel to our better understanding of the role of the immune system in neurologic diseases, there has been an increased availability in therapeutic options for autoimmune neurologic diseases such as multiple sclerosis, myasthenia gravis, polyneuropathies, central nervous system vasculitides and neurosarcoidosis. In many cases, the purported benefits of this class of therapy are anecdotal and not the result of good controlled clinical trials. Nonetheless, their potential efficacy is better known than their adverse event profile. A rationale therapeutic decision by the clinician will depend on a comprehensive understanding of the ratio between efficacy and toxicity. In this review, we outline the most commonly used immune suppressive medications in neurologic disease: cytotoxic chemotherapy, nucleoside analogues, calcineurin inhibitors, monoclonal antibodies and miscellaneous immune suppressants. A discussion of their mechanisms of action and related toxicity is highlighted, with the goal that the reader will be able to recognize the most commonly associated toxicities and identify strategies to prevent and manage problems that are expected to arise with their use.Keywords
This publication has 103 references indexed in Scilit:
- Mitoxantrone: benefits and risks in multiple sclerosis patientsNeurological Sciences, 2009
- Mutagenicity and Potential Carcinogenicity of Thiopurine Treatment in Patients with Inflammatory Bowel DiseaseCancer Research, 2009
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte functionNeurology, 2009
- INFLAMMATORY PSEUDOTUMOR ASSOCIATED WITH HIV, JCV, AND IMMUNE RECONSTITUTION SYNDROMENeurology, 2009
- Detection of JC virus DNA fragments but not proteins in normal brain tissueAnnals of Neurology, 2008
- Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosisNeurological Sciences, 2008
- Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Cardiotoxicity of Chemotherapeutic AgentsDrug Safety, 2000
- Mycophenolic acid for psoriasisJournal of the American Academy of Dermatology, 1987
- Azathioprine-associated acute pancreatitisDigestive Diseases and Sciences, 1977